Skip to main content
. 2020 Aug 19;9(4):955–970. doi: 10.1007/s40123-020-00292-4

Table 1.

Survey questions and aggregate responses

Question Average ± SD (or N (%) when applicable) Notes
1. Age 49.3 ± 12.6 Multiple-choice question allowing one answer (ages 28 through 100 allowed)
2. Gender Male: 60 (65.2%) Multiple-choice question
Female: 29 (31.5%)
Prefer not to say: 3 (3.3%)
3. Residency graduation year 2000.3 ± 13.4 Multiple-choice question allowing one answer (years 1948 through 2018)
4. US area of residency completion Midwest: 56 (60.9%) Multiple-choice question allowing one answer
Northeast: 17 (18.5%)
Southeast: 8 (8.7%)
Southwest: 8 (8.7%)
Northwest: 3 (3.3%)
5. Primary area of specialization General ophthalmology: 21 (22.8%) Multiple-choice question allowing one answer
Cornea/external eye disease: 20 (21.7%)
Glaucoma: (18, 19.6%)
Retina: 16 (17.4%)
Pediatrics: 8 (8.7%)
Neuro-ophthalmology: 5 (5.4%)
Oculoplastics: 3 (3.3%)
Uveitis: 1 (1.1%)
6. How many patients do you see on a normal clinic day? < 15: 3 (3.3%) Multiple-choice question allowing one answer

16–20: 6 (6.5%)

21–25: 10 (10.9%)

26–30: 21 (22.8%)
31–35: 15 (16.3%)
36–40: 17 (18.5%)
> 41: 20 (21.7%)
7. Do you perform surgical procedures? Yes: 81 (88%) Multiple-choice question allowing one answer
No: 11 (12%)
8. Do you feel that patient compliance is affected by generic usage vs. brand name? Yes, my patients are more compliant when using generics: 20 (21.7%) Multiple-choice question allowing one answer
Yes, my patients are more compliant when using brand names: 1 (1.1%)
No, my patient compliance is not affected to my knowledge: 53 (57.6%)
I have never looked into it: 18 (19.6%)
9. Which classes of drugs do you feel comfortable with prescribing generics over brand name? (all are drops unless otherwise indicated) Antibiotic–drops: 86 (93.5%) Multiple-choice question allowing one or more answers
Antibiotic–oral: 87 (94.6%)
Steroid–drops: 78 (84.8%)
Steroid-oral: 84 (91.3%)
Beta blocker: 84 (91.3%)
Carbonic anhydrase inhibitors: 82 (89.1%)
Prostaglandin analogs: 80 (87.0%)
Alpha agonists: 74 (80.4%)
Antihistamine: 72 (78.3%)
Antifungal: 46 (50%)
Sympathomimetics: 58 (63%)
Parasympathomimetics: 58 (63%)
Artificial tears: 66 (71.7%)
None: 1 (1.1%)
10. How often do drug representatives visit your clinic? Never: 27 (29.3%) Multiple-choice question allowing one answer
1–4 times per year: 22 (23.9%)
1–2 times per month: 23 (25.0%)
1–2 times per week: 11 (12.0%)
> 2 times per week: 9 (9.8%)
11. How well do you feel you know the availability of generic options for drugs you commonly prescribe? Practically not at all (1): 3 (3.3%) Likert scale from 1 to 5
2: 4 (4.3%)
3: 14 (15.2%)
4: 34 (37.0%)
Extremely well (5): 37 (40.2%)
12. How well do you feel you know the price differences between generics and brand-name drugs you commonly prescribe? Practically not at all (1): 11 (12.0%) Likert scale from 1 to 5
2: 14 (15.2%)
3: 33 (35.9%)
4: 27 (29.3%)
Extremely well (5): 7 (7.6%)
13. Do you often try to switch patients from brand-name drugs to generic drugs? Never (1): 8 (8.7%) Likert scale from 1 to 5
2: 9 (9.8%)
3: 26 (28.3%)
4: 39 (42.4%)
Always (5): 10 (10.9%)
14. Do you have any reservations about prescribing a generic drug in place of a brand-name drug? Check all that apply I have no reservations: 51 (55.4%) Multiple-choice question allowing one or more answers
Generics are less efficacious: 10 (10.9%)
Generics have less study data: 11 (12.0%)
Generics cause more side effects: 12 (13.0%)
Generics have additives that can vary based on batch which concerns me: 20 (21.7%)
Generics cause more adverse reactions: 10 (10.9%)
Generics have different colored tops which makes it hard for me to counsel my low vision patients on which drugs to take and how many drops to use: 11 (12.0%)
Generics get switched based on pharmacy contracts, and there is variation between generics that makes me uncomfortable for inconsistent treatment: 30 (32.6%)
I have financial interest that does not allow me to give an unbiased opinion on this matter: 0 (0%)
I do not feel I have enough knowledge about generics and therefore feel more comfortable with brand names: 2 (2.2%)

I feel that the drug representatives influence my decision to prescribe more brand names: 2 (2.2%)

Other: 7 (7.6%)

15. Do you know the difference in the approval process by the Food and Drug Administration for generic versus brand-name drugs?

I am not aware of a difference (1): 20 (21.7%)

2: 13 (14.1%)

3: 18 (19.6%)

4: 32 (34.8%)

I understand it very well (5): 9 (9.8%)

Likert scale from 1 to 5
16. Do you feel that you are aware of which patients are struggling financially?

Practically not at all (1): 2 (2.2%)

2: 9 (9.8%)

3: 38 (41.3%)

4: 32 (34.8%)

Extremely Well (5): 11 (12.0%)

Likert scale from 1 to 5
17. Do you feel your patients prefer generic drugs over brand-name drugs? Put 3 if you are unsure of any preference

My patients prefer brand-name drugs (1): 0 (0%)

2: 5 (5.4%)

3: 35 (38%)

4: 31 (33.7%)

My patients prefer generic drugs (5): 21 (22.8%)

Likert scale from 1 to 5
18. Does the severity of your patient’s disease make you more inclined to prescribe a brand-name drug over a generic?

Practically not at all (1): 31 (33.7%)

2: 17 (18.5%)

3: 23 (25.0%)

4: 18 (19.6%)

Extremely well (5): 3 (3.3%)

Likert scale from 1 to 5, with 1 being “never” and 5 being “always”
19. If severity does impact your decision, which is the correct reasoning you have for doing so?

If disease is more severe, I prescribe a brand name: 25 (30.1%)

If disease is more severe, I prescribe a generic: 0 (0%)

If disease is more severe, then I have less preference for brand vs. generic than I do when the disease is less severe: 2 (2.4%)

Severity does not impact my decision: 56 (67.5%)

Multiple-choice question allowing one answer
20. Do your patients ask about whether a new drug being prescribed is a generic or brand name?

Never (1): 20 (21.7%)

2: 29 (31.5%)

3: 21 (22.8%)

4: 19 (20.7%)

Always 5: 3 (3.3%)

Likert scale from 1 to 5
21. Do you (anecdotally) feel that patient outcome is affected by whether the brand name of a drug is used as opposed to its corresponding generic? Put 3 if you do not feel there is any difference in outcome

Better outcomes with generics (1): 1 (1.1%)

2: 1 (1.1%)

3: 72 (78.3%)

4: 18 (19.6%)

Better outcomes with brand-names (5): 0 (0.0%)

Likert scale from 1 to 5
22. If you had an eye disease, would you rather take a brand-name drug or a generic drug if both were FREE? Put 3 if you have no preference

Generic drug (1): 2 (2.2%)

2: 1 (1.1%)

3: 36 (39.1%)

4: 13 (14.1%)

Brand-name drug (5): 40 (43.5%)

Likert scale from 1 to 5
23. If you had an eye disease, would you rather take a brand-name drug or a generic drug? Put 3 if you have no preference

Generic drug (1): 10 (10.9%)

2: 7 (7.6%)

3: 40 (43.5%)

4: 20 (21.7%)

Brand-name drug (5): 15 (16.3%)

Likert scale from 1 to 5, with 1 being “generic drug” and 5 being “brand-name drug”
24. I would prescribe more generics if: check all that apply

I would still exhibit the same prescribing habits even if the following were done: 34 (37%)

If more data was available on generic efficacy: 30 (32.6%)

If I was more informed on the cost difference: 34 (37%)

If my patients asked for a generic: 37 (40.2%)

If the generics had the same color tops as the brand name type so I can counsel my low vision patients the same with generics as brand name: 21 (22.8%)

If I knew my patient would stay on only one generic brand rather than getting switched based on pharmacy contract/supply: 41 (44.6%)

If more data was available on long-term side effects/adverse reactions with generic drugs: 18 (19.6%)

If my patients felt more comfortable receiving a generic than they are now: 10 (10.9%)

If I was more aware of my patient’s financial situation: 16 (17.4%)

Multiple-choice question allowing one or more answers